Teva Pharmaceutical (TEVA) Gets a Buy from Barclays

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

CouponFollow Extension

$25.00
OFF

Teva Pharmaceutical (TEVA) Gets A Buy From Barclays

2 weeks from now

3 days ago · In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s …

businessinsider.com

$25.00
OFF

Teva Pharmaceutical (TEVA) Receives A Buy From Barclays

2 weeks from now

Oct 23, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $25.00. The company’s shares …

businessinsider.com

26%
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · TEVA. 1.26%. Barclays has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$25
OFF

Teva Price Target Raised To $25 From $22 At Barclays

2 weeks from now

Oct. 23, 2024, 03:45 AM. Barclays raised the firm’s price target on Teva (TEVA) to $25 from $22 and keeps an Overweight rating on the shares. The firm introduced Olanzapine into its model ...

businessinsider.com

$22.00
OFF

Sivik Global Healthcare LLC Sells 30,000 Shares Of Teva …

2 weeks from now

19 hours ago · Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an "overweight" rating in a report on …

marketbeat.com

$25.00
OFF

Barclays Lifts Teva Pharma Stock Target On Sales Potential

2 weeks from now

Oct 23, 2024 · Barclays (LON: BARC) has updated its outlook on Teva Pharmaceutical Industries Limited (NYSE: NYSE: TEVA), increasing the price target to $25.00 from the previous $22.00 …

investing.com

$14.00
OFF

Barclays Remains A Buy On Teva Pharmaceutical (TEVA)

2 weeks from now

Jun. 29, 2023, 04:15 AM. In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $14.00. …

businessinsider.com

$17.00
OFF

Barclays Sticks To Its Buy Rating For Teva Pharmaceutical (TEVA)

2 weeks from now

Feb 5, 2024 · Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $17.00. The company’s shares …

businessinsider.com

$10.00
OFF

Barclays Reaffirms Their Buy Rating On Amneal Pharmaceuticals …

2 weeks from now

3 days ago · Barclays analyst Balaji Prasad maintained a Buy rating on Amneal Pharmaceuticals (AMRX – Research Report) today and set a price target of $10.00. The company’s shares …

businessinsider.com

$20.00
OFF

Analysts Offer Insights On Healthcare Companies: Teva …

2 weeks from now

May 13, 2024 · In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical, with a price target of $20.00. The company’s shares closed …

businessinsider.com

FAQs about Teva Pharmaceutical (TEVA) Gets a Buy from Barclays Coupon?

Should you buy Teva Pharmaceutical (Teva)?

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. In a report released on October 16, UBS also maintained a Buy rating on the stock with a $26.00 price target. ...

Is Teva Pharmaceutical (Teva) overweight?

U.S.-listed shares of Teva Pharmaceutical ( NYSE: TEVA) are trading higher in the pre-market Tuesday after Barclays moved to upgrade the Israel-based generic drugmaker to Overweight from Equal Weight. The price target raised to $13 from $11 per share implies a premium of ~31% to the last close. ...

Where can I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Teva Pharmaceutical Industries own? ...

What did Teva Pharmaceutical Industries Ltd (Teva) do in Q2 2024?

Teva Pharmaceutical Industries Ltd (TEVA) Q2 2024 Earnings Call Highlights: Strong Revenue ... Teva Pharmaceutical Industries Ltd (TEVA) reports an 11% revenue increase and raises 2024 guidance amid innovative pipeline progress and strategic launches. ...

Should you buy Prasad pharmaceutical (Teva)?

According to TipRanks, Prasad has an average return of 3.0% and a 46.11% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $22.33 average price target, representing a 21.49% upside. ...

Why did Teva pay $450m?

Also Read: Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes. Galafold is a med Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). ...